Catalytic antioxidants to treat amyotropic lateral sclerosis.
Catalytic antioxidants are comprised of specialised classes of organometallic complexes that can catalyse the decomposition of injurious biological oxidants. These complexes have been shown to prevent the formation of several oxidative markers in spinal cord of G93A amyotropic lateral sclerosis mice and markedly extend survival, even when administered at symptom onset; however, it is now clear that some complexes lacking in antioxidant activity are also protective. New proteomics data suggest that these complexes also induce a broad spectrum of endogenous cellular defense mechanisms. The combination of antioxidant and adaptive resistance effects may explain the remarkable potency of these compounds and may also suggest wide applicability for them in a number of neurodegenerative diseases.
Crow
John P
JP
University of Arkansas for Medical Sciences, College of Medicine, 4301 W. Markham Slot 638, Little Rock, AR 72205, USA. jpcrow@uams.edu
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy* / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D004195:Disease Models, Animal; D015507:Drugs, Investigational / Q000627:therapeutic use*; D006801:Humans; D008665:Metalloporphyrins / Q000627:therapeutic use*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010084:Oxidation-Reduction; D013482:Superoxide Dismutase / Q000378:metabolism
D000975:Antioxidants; D015507:Drugs, Investigational; D008665:Metalloporphyrins; D009942:Organometallic Compounds; D013482:Superoxide Dismutase